Bioconjugates

Overview of ADC Conjugation Technology

by
Overview of ADC Conjugation Technology

–01– Introduction For decades, advancements in antibody-drug conjugates (ADC) and bioconjugates have revolutionized targeted therapies for various diseases. Unlike traditional chemotherapy, ADCs selectively target tumor cells while sparing normal cells, making them highly suitable for cancer treatment. Currently, there are 17 types of ADCs approved by regulatory agencies in different countries worldwide. Over 200 more … Read more

Understanding DAC Design Points and Representative Cases in PROTAC

by
Understanding DAC Design Points and Representative Cases in PROTAC

Protein Hydrolysis Targeted Chimeras (PROTAC) are bringing revolutionary changes to the fields of biology and medicinal chemistry. PROTAC consists of a target protein ligand, an E3 ligase ligand, and a spacer group[Unlike the linker used in antibody-drug conjugates, here we specifically use “spacer” instead of the commonly seen “linker” in PROTAC literature]. PROTAC structural composition … Read more